Asset Details
Do you wish to reserve the book?
Real-world experience with early use of vericiguat in worsening heart failure
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Real-world experience with early use of vericiguat in worsening heart failure
Do you wish to request the book?
Real-world experience with early use of vericiguat in worsening heart failure
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Real-world experience with early use of vericiguat in worsening heart failure
2025
Overview
Despite guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), a residual risk of adverse outcomes persists, particularly after worsening heart failure (WHF). The VICTORIA trial demonstrated the benefit of adding vericiguat in high-risk patients. However, its real-world adoption in Italy remains unclear. The aim of this study was to assess the use, safety, and prescription patterns of vericiguat in Italian patients with recent WHF.
The multicenter VeriChange survey was conducted across 28 hospitals in Northern Italy. A total of 399 anonymized clinical records of HFrEF patients with recent WHF were collected. The survey included demographic, clinical, therapeutic data and safety outcomes.
Overall, 68% of patients were classified as NYHA III-IV and 77% had a left ventricular ejection fraction ≤35%. Vericiguat was initiated after the first WHF episode in 54% of cases, and during hospitalization in 50%. The target dose of 10 mg/day was reached in 56% of patients. Tolerability was high, with only 3% treatment discontinuation. Prescription occurred in a context of strong adherence to guideline-based therapy.
Vericiguat was introduced early and safely in Italian real-world practice, especially in tertiary and referral centers. Broader implementation and earlier WHF recognition are still needed to reduce residual risk in advanced heart failure patients.
Publisher
Il Pensiero Scientifico Editore
Subject
/ Female
/ Heart Failure - drug therapy
/ Heart Failure - physiopathology
/ Heterocyclic Compounds, 2-Ring - administration & dosage
/ Heterocyclic Compounds, 2-Ring - adverse effects
/ Humans
/ Italy
/ Male
/ Pyrimidines - administration & dosage
/ Pyrimidines - adverse effects
